Roche Reports P-III (lidERA Breast Cancer) Trial Data on Giredestrant for Early Breast Cancer

Shots:

• Roche has reported P-III (lidERA Breast Cancer) trial assessing giredestrant (QD) vs SoC endocrine therapy in pts (n=~4,100) with medium or high-risk stage I-III ER+, HER2- breast cancer
• At the interim analysis, trial met its 1EP of improved invasive disease-free survival (iDFS) by 30%, with 92.4% vs 89.6% pts alive & invasive disease free at 3yrs.; iDFS benefit was consistent across all clinically relevant subgroups
• Giredestrant also demonstrated a 31% risk reduction of distant recurrence-free interval, plus trial showed a favorable OS trend, with OS evaluation to continue in future; results were presented at SABCS’25

Ref: Roche | Image: Roche |Press Release

Related News: Roche’s Point-of-Care PCR Test Gains FDA’s 510(k) Clearance with CLIA Waiver and European CE Mark to Diagnose Bordetella infections

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com